(NAR) VOL. 29 NO. 1/ JANUARY - MARCH 18
“ The Board shall be assisted by a Committee on Reclassification, Addition, or Removal of any Drug/Substance from the List of Dangerous Drugs/Controlled Precursors and Essential Chemicals composed of two (2) permanent Members of the Board, the NGO Representative, and representatives from the Department of Justice, Food and Drug Administration, Department of Health-Pharmaceutical Division, UP-PGH National Poison Management and Control Center, Philippine Drug Enforcement Agency, National Bureau of Investigation, and PNP Crime Laboratory. One Permanent Member shall act as Chairperson and preside over the meetings while the Executive Director shall act as the Head Secretariat of the Committee”2. That in case any provision of this Regulation is declared invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions and that of the amended Regulation shall not in any way be affected or impaired.
“ The Committee shall gather, collect and analyze data relative to a drug and/or substance under question, taking into consideration the criteria and procedure set forth in Section 93 of the Act. It shall have the authority to conduct public hearings as provided under Section 3(1) (b) of Board Regulation No. 1, series of 2014 and invite experts in the field of drug prevention and control who shall provide recommendations to the Committee during consultation meetings. Thereafter, the Committee shall submit a report of its findings and recommendation(s) to the Board.
Experts invited by the Committee shall be entitled to honoraria, transportation or representation allowance subject to pertinent government accounting and auditing rules and regualtions. The Committee shall take seteps to ensure that no conflict of interest will arise in inviting experts during meetings and deliberations.”